Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone + Amantadine for Levodopa-induced Dyskinesia
NCT02589340Phase 1Terminated
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing Buspirone Sequence with Placebo Sequence (2 arms). Primary endpoints: Area Under the Curve - Dyskinesia - Forceplate, Unified Dyskinesia Rating Scale up to 6 weeks and 1 more. Started Jan 2016; status: terminated.
02
Drugs
buspirone
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02589340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589340.